IDT Australia Limited (ASX: IDT) is approaching a significant financial milestone, forecasting a return to positive EBITDA in FY27 as its pharmaceutical manufacturing turnaround gathers momentum.
With improving cash flow, new long-term manufacturing contracts and a $50 million annual revenue target for FY29, the company is building a stronger foundation for growth. Its latest operating update highlights an encouraging shift from restructuring towards expanding revenue and operating profitability.
Key Numbers Behind IDT's Growth Outlook
- $19 million to $20 million: FY27 core revenue guidance, representing projected growth of approximately 13% to 19%.
- $1 million to $1.5 million: Forecast FY27 EBITDA, compared with a $922,000 loss in FY26.
- $16.8 million: FY26 comparable core revenue, up 16.5% from $14.4 million in FY25.
- $1.07 million: Positive FY26 operating cash flow, reversing a $6.25 million outflow in FY25.
- $50 million: Targeted annual revenue by FY29, representing almost three times FY26 core revenue.
FY27 Guidance Points to an Important Earnings Breakthrough
IDT's 18 November 2026 operating update reinforces its improving financial outlook, with management expecting positive EBITDA for FY27.
The forecast represents a substantial improvement from FY26 and reflects the benefits of operational restructuring, growing manufacturing activity and a stronger customer pipeline.
Several major customer contracts are expected to commence during the second half of FY27, providing additional opportunities to expand revenue.
The company has also secured a five-year agreement with an existing radiopharmaceutical customer, strengthening its position in specialised pharmaceutical manufacturing.
Although the contract's financial value remains undisclosed, the longer-term relationship offers improved visibility over future manufacturing activity.
What Stands Out: Stronger Cash Flow and Operating Leverage
One of IDT's most encouraging developments is the improvement in its underlying financial performance.
FY26 EBITDA losses narrowed approximately 85%, from $6.3 million in FY25 to $922,000.
Importantly, the company also delivered $1.07 million in positive operating cash flow, compared with a $6.25 million outflow in the previous year.
This turnaround suggests IDT's operational improvements are beginning to translate into tangible financial benefits.
The company remains focused on improving profitability as manufacturing volumes increase, potentially allowing additional revenue to contribute more efficiently to earnings.
While FY26 statutory losses remained at $2.72 million and borrowings totalled approximately $10.82 million at 30 June 2026, improving operating cash generation provides a more constructive foundation for expansion.
What IDT Australia Is Doing Now
IDT is undertaking an approximately $7 million manufacturing upgrade programme at its Boronia facility in Victoria.
The investment is designed to expand sterile manufacturing capabilities, including production of pre-filled syringes and cartridges.
These upgrades position the company to pursue opportunities involving biologics, antibody drug conjugates, mRNA therapies and other specialised injectable treatments.
IDT is also strengthening its solid oral manufacturing capabilities to accommodate more complex pharmaceutical production requirements.
Its established relationships with pharmaceutical companies, including Sanofi, support its strategy of securing larger, longer-duration manufacturing programmes.
Together, these initiatives could improve facility utilisation, strengthen customer retention and create additional revenue opportunities.
Insight: Can IDT's Manufacturing Expansion Unlock Its Next Growth Phase?
We think IDT's improving financial performance and expanding manufacturing capabilities provide a promising foundation for its next growth phase. The transition towards positive EBITDA, combined with stronger operating cash flow and longer-term customer relationships, suggests its turnaround strategy is delivering measurable progress. Its specialised infrastructure and regulatory credentials also support a competitive position in pharmaceutical manufacturing. While achieving $50 million in annual revenue by FY29 remains ambitious, successful contract execution and improved capacity utilisation could strengthen the company's earnings profile. Sustained cash generation will be the key measure of success.
What Happens Next?
The second half of FY27 could prove particularly important as IDT begins delivering several larger manufacturing contracts.
Successful execution, increasing manufacturing volumes and continued improvements in operating cash flow would provide further evidence of the company's progress towards sustainable profitability.
The manufacturing upgrade programme also creates opportunities to pursue more sophisticated pharmaceutical contracts over the coming years.
Although additional funding requirements, project execution and contract timing remain considerations, IDT enters this next phase with improving operational momentum and a clearer earnings outlook.
With positive FY27 EBITDA now within management's expectations and a $50 million revenue ambition for FY29, IDT Australia is building a compelling longer-term manufacturing growth story.